Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

The fraction of life years lost after diagnosis (FLYLAD): a person-centred measure of cancer burden

Title: The fraction of life years lost after diagnosis (FLYLAD): a person-centred measure of cancer burden
Authors: Banham, D.; Karnon, J.; Brown, A.; Roder, D.; Lynch, J.
Source: http://dx.doi.org/10.1186/s12963-023-00314-w.
Publisher Information: Springer Science and Business Media LLC
Publication Year: 2023
Collection: The University of Adelaide: Digital Library
Subject Terms: Indigenous Australians; Cancer; Premature mortality; Mortality to incidence ratio; Disparity; Burden of disease; Humans; Australia; Health Facilities; Life Expectancy; Life Tables; Mortality; Premature; Neoplasms; DNA-Binding Proteins; Nuclear Proteins
Description: Background: Cancer control initiatives are informed by quantifying the capacity to reduce cancer burden through effective interventions. Burden measures using health administrative data are a sustainable way to support monitoring and evaluating of outcomes among patients and populations. The Fraction of Life Years Lost After Diagnosis (FLYLAD) is one such burden measure. We use data on Aboriginal and non-Aboriginal South Australians from 1990 to 2010 to show how FLYLAD quantifies disparities in cancer burden: between populations; between sub-population cohorts where stage at diagnosis is available; and when follow-up is constrained to 24-months after diagnosis. Method: FLYLADcancer is the fraction of years of life expectancy lost due to cancer (YLLcancer) to life expectancy years at risk at time of cancer diagnosis (LYAR) for each person. The Global Burden of Disease standard life table provides referent life expectancies. FLYLADcancer was estimated for the population of cancer cases diagnosed in South Australia from 1990 to 2010. Cancer stage at diagnosis was also available for cancers diagnosed in Aboriginal people and a cohort of non-Aboriginal people matched by sex, year of birth, primary cancer site and year of diagnosis. Results: Cancers diagnoses (N = 144,891) included 777 among Aboriginal people. Cancer burden described by FLYLADcancer was higher among Aboriginal than non-Aboriginal (0.55, 95% CIs 0.52-0.59 versus 0.39, 95% CIs 0.39-0.40). Diagnoses at younger ages among Aboriginal people, 7 year higher LYAR (31.0, 95% CIs 30.0-32.0 versus 24.1, 95% CIs 24.1-24.2) and higher premature cancer mortality (YLLcancer = 16.3, 95% CIs 15.1-17.5 versus YLLcancer = 8.2, 95% CIs 8.2-8.3) influenced this. Disparities in cancer burden between the matched Aboriginal and non-Aboriginal cohorts manifested 24-months after diagnosis with FLYLADcancer 0.44, 95% CIs 0.40-0.47 and 0.28, 95% CIs 0.25-0.31 respectively. Conclusion: FLYLAD described disproportionately higher cancer burden among Aboriginal people in comparisons ...
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 1478-7954
Relation: http://purl.org/au-research/grants/nhmrc/APP1072243; Population Health Metrics, 2023; 21(1):1-14; https://hdl.handle.net/2440/139540; Karnon, J. [0000-0003-3220-2099]; Brown, A. [0000-0003-2112-3918]; Roder, D. [0000-0001-6442-4409]; Lynch, J. [0000-0003-2781-7902]
DOI: 10.1186/s12963-023-00314-w
Availability: https://hdl.handle.net/2440/139540; https://doi.org/10.1186/s12963-023-00314-w
Rights: © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Accession Number: edsbas.354624D5
Database: BASE